Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder, Schizophrenia
About this trial
This is an interventional basic science trial for Schizophrenia and Disorders With Psychotic Features focused on measuring Nicotine Dependence, Tobacco Dependence
Eligibility Criteria
Inclusion Criteria: Smokes between 20 and 50 cigarettes per day Diagnosis of schizophrenia or schizoaffective disorder Exclusion Criteria: If enrolled in the control group, must not be diagnosed with a psychiatric disorder Currently dependent on alcohol or any drug (other than nicotine) Currently trying to quit smoking Currently taking bupropion, desipramine, clonidine, buspirone, or doxepin History of liver disease History of heart attacks or chest pain Allergic to adhesives Pregnant or breastfeeding
Sites / Locations
- Providence VA Medical Center
- Brown University
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Placebo Comparator
1
2
3
Transdermal nicotine, 42 mg
Transdermal nicotine, 21 mg
placebo patch